Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, January 21, 2011

abstract: Bleeding events in (Avastin) bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

Conclusions:
These data suggest that bevacizumab did not increase the risk of severe bleeding in cancer patients who received

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.